{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-029143","form_type":"8-K","ticker":"ADMA","cik":"0001368514","company_name":"ADMA BIOLOGICS, INC.","filed_at":"2025-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.826063+00:00","generated_at":"2026-05-17T19:01:23.432323+00:00","sec_items":["1.01","1.02","2.02","2.03","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"ADMA Biologics Q2 revenue up 29% underlying; launches yield-enhanced IG mfg","bullets":["Q2 2025 total revenue $122.0M, up 14% YoY (29% excluding $12.6M prior-year Medicaid reversal).","GAAP net income $34.2M; Adjusted EBITDA $50.8M, up 59% YoY underlying.","Began commercial-scale yield-enhanced IG manufacturing delivering 20%+ output gain.","Closed $300M J.P. Morgan-led financing ($75M term loan, $225M revolver) replacing Ares debt.","Reaffirmed FY2025-2026 guidance; pre-2030 revenue target $1.1B+; repurchased $15M stock."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-029143","json":"https://secwatch.observer/filing/0001140361-25-029143.json","markdown":"https://secwatch.observer/filing/0001140361-25-029143.md","text":"https://secwatch.observer/filing/0001140361-25-029143.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1368514/000114036125029143/0001140361-25-029143-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1368514/000114036125029143/ef20053140_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T19:01:23.432323+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"65d79af5e31b317cc6c92c7aaa937d772468ff0a","claim":"ADMA BIOLOGICS, INC. incurred term loan of $75 million with JPMorgan Chase Bank, N.A. at 150 basis points to 200 basis points over the alternate base rate and 250 basis maturing August 5, 2028.","evidence_excerpt":"The Credit Agreement provides for $300 million of senior secured credit facilities, consisting of (a) a term loan in the aggregate principal amount of $75 million (the \"Term Loan Facility\") and (b) a revolving credit facility in the aggregate principal amount of $225 million (the \"Revolving Facility\").","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036125029143/0001140361-25-029143-index.htm","confidence":0.95,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"term loan"},{"label":"Principal","value":"$75 million"},{"label":"Counterparty","value":"JPMorgan Chase Bank, N.A."},{"label":"Rate","value":"150 basis points to 200 basis points over the alternate base rate and 250 basis"},{"label":"Maturity","value":"August 5, 2028"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"780258111d7065885275191180df0211cc6827a2","claim":"ADMA BIOLOGICS, INC. incurred revolving credit of $225 million with JPMorgan Chase Bank, N.A. at 150 basis points to 200 basis points over the alternate base rate and 250 basis maturing August 5, 2028.","evidence_excerpt":"The Credit Agreement provides for $300 million of senior secured credit facilities, consisting of (a) a term loan in the aggregate principal amount of $75 million (the \"Term Loan Facility\") and (b) a revolving credit facility in the aggregate principal amount of $225 million (the \"Revolving Facility\").","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036125029143/0001140361-25-029143-index.htm","confidence":0.95,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"revolving credit"},{"label":"Principal","value":"$225 million"},{"label":"Counterparty","value":"JPMorgan Chase Bank, N.A."},{"label":"Rate","value":"150 basis points to 200 basis points over the alternate base rate and 250 basis"},{"label":"Maturity","value":"August 5, 2028"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"b269ccc296b5b23e792f4e75018f44f45ae342c8","claim":"ADMA BIOLOGICS, INC. incurred credit facility of $300 million with JPMorgan Chase Bank, N.A. at 150 basis points to 200 basis points over the alternate base rate and 250 basis maturing August 5, 2028.","evidence_excerpt":"into a Credit Agreement (the “Credit Agreement”), with the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent. The Credit Agreement provides for $300 million of senior secured credit facilities, consisting of (a) a term loan in the aggregate principal amount of $75 million (the “Term Loan Facility”) and (b) a revolving credit","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036125029143/0001140361-25-029143-index.htm","confidence":0.95,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"credit facility"},{"label":"Principal","value":"$300 million"},{"label":"Counterparty","value":"JPMorgan Chase Bank, N.A."},{"label":"Rate","value":"150 basis points to 200 basis points over the alternate base rate and 250 basis"},{"label":"Maturity","value":"August 5, 2028"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}